alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
IV 

114TH CONGRESS 

1ST SESSION H. RES. 418 

Expressing support for designation of the week of September 15, 2015, 

through September 21, 2015, as ‘‘Balance Awareness Week’’. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 11, 2015 

Ms. EDDIE BERNICE JOHNSON of Texas (for herself and Mr. HASTINGS) submitted the following resolution; which was referred to the Committee on 

Energy and Commerce 

RESOLUTION 

Expressing support for designation of the week of September 

15, 2015, through September 21, 2015, as ‘‘Balance 

Awareness Week’’. 

Whereas vestibular (inner-ear-balance) disorders are underdiagnosed and undertreated; 

Whereas as many as 35 percent of adults 40 years of age and 

older in the United States, approximately 69,000,000 

people in the United States, have experienced some form 

of vestibular dysfunction; 

Whereas 80 percent of people 65 years of age and older have 

experienced dizziness; 

Whereas vestibular disorder patients may consult 4 or more 

physicians and spend 50 months or more in their search 

for a diagnosis; 


emcdonald on DSK67QTVN1PROD with BILLS
2 

•HRES 418 IH 

Whereas the Vestibular Disorders Association celebrates 

‘‘Balance Awareness Week’’ to reduce the time it takes 

to diagnose a vestibular disorder by helping patients recognize their symptoms and encouraging them to seek 

help from a qualified vestibular specialist; and 

Whereas the week of September 15, 2015, through September 21, 2015, would be an appropriate week to designate as ‘‘Balance Awareness Week’’: Now, therefore, be 

it 

1 Resolved, That the House of Representatives— 

2 (1) supports the designation of ‘‘Balance 

3 Awareness Week’’; and 

4 (2) recognizes the importance of raising public 

5 awareness about vestibular disorders. 

Æ 


emcdonald on DSK67QTVN1PROD with BILLS
COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 02-13-00096-CV

Jason E. Haddock

v.

Texas Workforce Commission and 

Adecco USA Inc.

§

§

§

§

From County Court at Law No. 1

of Tarrant County (2011-002290-1)

October 17, 2013

Opinion by Justice McCoy

JUDGMENT

This court has considered the record on appeal in this case and holds that 

there was no error in the trial court’s judgment. It is ordered that the judgment of 

the trial court is affirmed.

It is further ordered that appellant Jason E. Haddock shall pay all costs of 

this appeal, for which let execution issue.

SECOND DISTRICT COURT OF APPEALS 

By _________________________________

 Justice Bob McCoy
FOR INFORMATION AND ACTION

DA-2021-22

August 13, 2021

Subject: APHIS Removes Pale Cyst Nematode (Globodera pallida) Associated Fields 

from Regulation in Idaho

To: State and Territory Agricultural Regulatory Officials

On July 13, 2021, the Animal and Plant Health Inspection Service (APHIS) released two pale 

cyst nematode (PCN) associated fields, which have a combined area of approximately 271 acres,

from regulation in Bingham County, Idaho. APHIS released the fields because the fields have 

completed a release protocol comprised of a sequence of surveys with negative laboratory results 

for PCN, in accordance with 7 CFR §301.86, subpart 3(d)(2).

With these changes, the current regulated area is 7,083 acres, of which 3,446 acres are infested 

fields, and 3,637 are associated fields. The infested fields are in an 8.5-mile radius that spans a 

portion of northern Bingham County and southern Bonneville County.

APHIS will follow up with a notice of this change to the regulated area in the Federal Register. 

The specific PCN-regulated areas are on the following website:

https://www.aphis.usda.gov/aphis/ourfocus/planthealth/plant-pest-and-disease-programs/pestsand-diseases/nematode/pcn

For additional information about the PCN program, please contact the National Policy Manager, 

Lynn Evans-Goldner, at 301-851-2286.

Dr. Osama El-Lissy

Deputy Administrator

Plant Protection and Quarantine
Charge Questions: Moiemen et al. (2011)

Study Title: 

### Moiemen, N.S., Shale, E., Drysdale, K.J., Smith, G., Wilson, Y.T., Rapini, R. Acticoat dressings and major burns: Syst emic silver absorption. The Midlands Burn Centre, University Hospitals Birmingham Foundation Trust, United Kingdom. Burns, 37, 27-35 (2011). (MRID 48607501)

1. Is the Moiemen et al. (2011) study scientifically sound, providing reliable data?

2. If so, can the Moiemen et al. (2011) study be used to support the Agency's conclusion that the dermal absorption factor for silver from nanosilver on human skin is less than 0.1%?

3. Is there adequate information to support a determination that the study was conducted in substantial compliance procedures at least as protective as those at subparts A-L of 40 CFR

Part 26?
<PAGE>
 
                                  EXHIBIT 11

             AMERICAN BUSINESS INFORMATION, INC. AND SUBSIDIARIES
             STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS
              For the three months ended March 31, 1996 and 1995
                   (In thousands, except per share amounts)

<TABLE>
<CAPTION>
                                                                                   Three Months Ended
                                                                                        March 31
                                                                                -----------------------
                                                                                 1996             1995
                                                                                 ----             ----
<S>                                                                            <C>              <C>
Average shares outstanding  . . . . . . . . . . . . . . . . . . . . . . . .     20,783           20,685
Net additional common equivalent shares . . . . . . . . . . . . . . . . . .        137              351
                                                                               -------          -------
Average number of common and common equivalent
  shares outstanding  . . . . . . . . . . . . . . . . . . . . . . . . . . .     20,920           21,036
                                                                               =======          =======

Net income for per share computation  . . . . . . . . . . . . . . . . . . .    $ 4,709          $ 3,813
                                                                               =======          =======

Net income per average common and common
   equivalent share outstanding (1) . . . . . . . . . . . . . . . . . . . .    $  0.23          $  0.18
                                                                               =======          =======
</TABLE>
____________________

(1)  This calculation is submitted pursuant to Regulation S-K item 601(b)(11)
     although not required by footnote 2 to paragraph 14 of APB Opinion No. 15
     because it will result in dilution of less than 3 percent.
#### State v. Kaneshiro

23642

03/27/2002

Affirmed
EXHIBIT 23

















                                       78


<PAGE>


                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

To Surgical Laser Technologies, Inc.:

As independent public accountants, we hereby consent to the inclusion in this
Form 10-K of our report dated January 30, 1998. It should be noted that we have
not audited any financial statements of the Company subsequent to December 28,
1997, or performed any audit procedures subsequent to the date of our report.

                                                          ARTHUR ANDERSEN LLP


Philadelphia, Pa.
   March 23, 1998


                                       79

<PAGE>


                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

To Surgical Laser Technologies, Inc.:

As independent public accountants, we hereby consent to the incorporation of our
report included in this Form 10-K, into the Company's previously filed Form S-8
Registration Statements File Nos. 33-32835, 33-38748, 33-42451, 33-49730,
33-83074 and 333-19229.

                                                            ARTHUR ANDERSEN LLP


Philadelphia, Pa.
   March 23, 1998


                                       80
Exhibit



	
		
	
	

Exhibit 10(c)































May 31, 2018


Kate Ramundo
1 Sussex Avenue
Bronxville, NY 10708




Dear Kate:


I am pleased to confirm that you were issued 55,530 restricted stock units (RSUs) as a special retention award valued at $1,000,095 on the grant date of May 16, 2018 (based on the Arconic closing stock price of $18.01 on that date).  The award will vest in full on December 31, 2019, subject to your continued employment through that date.  This award is a demonstration of our continuing commitment to you.  The enclosed Fact Sheet outlines the terms and conditions of the grant.  


Furthermore, per our discussion, if you decide not to relocate to Virginia, your termination (other than termination for cause) or your voluntary resignation will be considered a Severance Event under the Arconic Executive Severance Plan, for which you will be entitled to receive severance payments and benefits thereunder, provided that your last day with Arconic is not earlier than September 30, 2018 and not later than June 30, 2020.


We look forward to your continued contributions toward our success.




Sincerely,


/s/ Chip Blankenship


Chip Blankenship
[Federal Register Volume 88, Number 231 (Monday, December 4, 2023)]
[Notices]
[Page 84166]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26553]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1304]


Bulk Manufacturer of Controlled Substances Application: Element 
Materials Technology Santa Rosa

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Element Materials Technology Santa Rosa has applied to be 
registered as a bulk manufacturer of basic class(es) of controlled 
substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for 
further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
February 2, 2024. Such persons may also file a written request for a 
hearing on the application on or before February 2, 2024.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on https://www.regulations.gov. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on November 1, 2023, Element Materials Technology Santa 
Rosa, 3331 Industrial Drive, Suite B, Santa Rosa, California 95403-
2062, applied to be registered as a bulk manufacturer of the following 
basic class(es) of controlled substance(s):

------------------------------------------------------------------------
                                         Drug
         Controlled substance            code           Schedule
------------------------------------------------------------------------
Oxymorphone...........................    9652  II
Fentanyl..............................    9801  II
------------------------------------------------------------------------

    The company is a contract manufacturer. At the request of the 
company's customers, it manufactures derivatives of the listed 
controlled substances in bulk form. No other activities for these drug 
codes are authorized for this registration.

Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-26553 Filed 12-1-23; 8:45 am]
BILLING CODE 4410-09-P
24274

#### State v. Klein

Affirmed
I 

J 

J 

J 

l 

J 

J 

- I 

--, 

l 

J 

l 

r----

,------

I 

I 

l 

I 

l J 

l 

J 

j 

J 

l 

t l I I 

I 

J 

J 

J 

l 

J 

J 

According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number. The valid OMB control numbers for this information collection are 0579-0020 and 0579-0036. The time required to complete this information collection is estimated to average .13 to .25 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

No dog, cat, nonhuman primate, or additional kinds or USDA regulations shall be delivered to any intermediate in commerce unless accompanied by a health certificate veterinarian (7 U.S.C. 21.43.9; CFR, Subchapter A, Part 

UNITED STATES DEPARTMENT OF AGRICULTURE 

ANIMAL AND PLANT HEALTH INSPECTION SERVICE

UNITED STATES INTERSTATE AND INTERNATIONAL

CERTIFICATE OF HEALTH EXAMINATION

FOR SMALL ANIMALS

WARNING: Anyone who makes a false, fictitious, or fraudulent statement on this document, or uses such document knowing it to be false, fictitious, or fraudulent may be subject to a fine of not more than $10,000 or imprisonment of not more than 5 years or both (18 U.S.C. 1001).

1. TYPE OF ANIMAL SHIPPED (select one only)

Dog Other_________________ Cat 

Nonhuman Primate Ferret Rodent 

2. CER

3. TOTAL NUMBER OF ANIMALS 4. PAG

5. NAME, ADDRESS, AND TELEPHONE NUMBER OF OWNER (CONSIGNOR) USDA License/or Registration Number (if applicable) 

6. NAME, ADDRESS, AND TELEPHONE NUMBER OF RECIPIENT AT DEST

7. ANIMAL IDENTIFICATION 8. PERTINENT VACCINATION, TREATMENT, AND 

NAME, AND/OR TATTOO NUMBER 

OR OTHER IDENTIFICATION

BREED – COMMON

OR SCIENTIFIC

NAME 

AGE SEX

COLOR OR

DISTINCTIVE 

MARKS OR 

MICROCHIP 

RABIES VACCINATION 

1 YEAR 2 YEARS 3 YEARS 

TREATM

Vaccination Date Product Date 

(1) (2) (3) (4) (5) (6) 9. REMARKS OR ADDITIONAL CERTIFICATION STATEMENTS (WHEN REQUIRED) VETERINARY CERTIFICATION: I certify that the animals described in box 7 ha

information provided in box 8 is true and accurate to the best of my knowledge, (“X” applicable statements). 

I have verified the presence of the microchip, if a microchip is listed in box 7.I certify that the animal(s) described above and on continuation sheet(s), if appl

appear to be free of any infectious or contagious diseases and to the best of my knowl

animal or other animals or would endanger public health.

To my knowledge, the animal(s) described above and on continuation sheet(s) 

for rabies and has/have not been exposed to rabies.

ENDORSEMENT FOR INTERNATIONAL EXPORT (IF NEEDED) PRINTED NAME OF USDA VETERINARIAN 

NAME, ADDRESS, AND TELEPHONE NUMBER OF ISSUING VETERINARIA

NOTE: International shipments may require certification by an accredited veterinarian.

SIGNATURE OF USDA VETERINARIAN Apply USDA Seal or Stamp here DATE SIGNATURE OF ISSUING VETERINARIAN 

APHIS Form 7001 (NOV 2010) This certificate is valid for 30 days after issuance
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the balance
sheet of CNL Income Fund XII, Ltd. at September 30, 1997, and its statement of
income for the nine months then ended and is qualified in its entirety by
reference to the Form 10Q of CNL Income Fund XII, Ltd. for the nine months ended
September 30, 1997.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                       1,812,974
<SECURITIES>                                         0
<RECEIVABLES>                                  218,717
<ALLOWANCES>                                    28,360
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0<F1>
<PP&E>                                      22,281,166
<DEPRECIATION>                               1,381,329
<TOTAL-ASSETS>                              41,508,301
<CURRENT-LIABILITIES>                                0<F1>
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  40,362,762
<TOTAL-LIABILITY-AND-EQUITY>                41,508,301
<SALES>                                              0
<TOTAL-REVENUES>                             3,157,454
<CGS>                                                0
<TOTAL-COSTS>                                  428,628
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              2,941,412
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          2,941,412
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,941,412
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
<FN>
<F1>Due to the nature of its industry, CNL Income Fund XII, Ltd. has an
unclassified balance sheet; therefore no values are shown above for current
assets and current liabilities.
</FN>
        



</TABLE>
According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information 

unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0579-0430. The time required to complete this 

information collection is estimated to average 2 minutes per response, including the time for reviewing instructions, search existing data sources, gathering and 

maintaining the data needed, and completing and reviewing the collection of information. 

OMB APPROVED 

0579-0430 

Exp. 02/2025

UNITED STATES DEPARTMENT OF AGRICULTURE 

ANIMAL AND PLANT HEALTH INSPECTION SERVICE 

VETERINARY SERVICES 

NATIONAL VETERINARY SERVICES LABORATORIES 

KIT AND INSTRUMENT ORDER FORM 

CONTACT NAME: 

ORGANIZATION COMPANY: 

ADDRESS (do not use a P.O. Box) CITY, STATE, ZIP CODE: 

TELEPHONE NUMBER: DATE OF REQUEST: 

ITEM QUANTITY ITEM QUANTITY 

BSE FRESH TISSUE DIAGNOSTIC KITS 

KIT #5 (5 red-top tubes) LARGE 

KIT #10 (10 red-top tubes) SMALL 

KIT #25 (25 red-top tubes) 

SCRAPIE (Formalin) INSTRUMENTS 

KIT #1 (2-180 ml jars) SPOONS, SMALL 

KIT #2 (12-180 ml jars) SPOONS, LARGE 

KIT #3 (2-90 ml jars) FORCEPS (rat tooth) 

KIT #4 (12-90 ml jars) METZENBAUM SCISSORS (curved nose) 

TB KITS DRESSING SCISSORS (straight nose) 

SLAUGHTER (black/yellow) SCALPELS (10 per box) 

DEER (orange) RECTAL SPECULUM 

MEDIA MISCELLANEOUS KITS 

TBTB 5 ml (10/box) 

FADD REPLENISHMENT 

TBTB 3 ml (each) 

3 ml BHI BROTH (40 tubes/box; no antibiotics) 

(Blue cap/plastic tube. For up to 5 swabs OP/CL swab pools from 

avian spp. See NVSL WI-AV-0020 for details.) 

AI KITS 

5.5 ml BHI BROTH WITH ANTIBIOTICS (40 tubes/box) 

(Black cap/plastic tube. For up to 11 TR/OP swab pools from 

gallinaceous poultry or environmental sample collection; 

Refer to NVSL WI-AV-0020 for further details.) 

COLLECTION KIT (STP 210) 

FORMALIN CASE SIZE MISCELLANEOUS ITEMS 

90 ml (96/case) AI BAR CODES (4/set) (Specify roll or set) 

180 ml (64/case) BSE BAR CODES (8/set) (Specify roll or set) 

TISSUE CASSETTE 

BIOPSY SPONGES 

Fax all supply orders to NVSL Shipping Department at 515-337-7378 or email to NVSLShipping@usda.gov. 

The NVSL Shipping Department may be reached at NVSLShipping@usda.gov. 

Safety data sheets may be obtained at 

https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/sa_lab_information_services/sa_reagents/ct_safety 

Please make a copy of all orders for your records. 

VS FORM 4-12 

FEB 2021
IN THE

TENTH COURT OF APPEALS

No. 10-12-00022-CV

WILLIE EDWARD DAVIS,

Appellant

v.

CHRIS KIRK,

Appellee

From the 361st District Court

Brazos County, Texas

Trial Court No. 11-001773-CV-361

MEMORANDUM OPINION

Willie Edward Davis, a prison inmate, appeals the dismissal of his lawsuit 

against Chris Kirk. By letter dated February 23, 2012, the Clerk of this Court notified 

Davis that the clerk’s record had not been filed because he had either failed to pay or 

make arrangement to pay the clerk’s fee for preparation of the clerk’s record. The Clerk 

also warned Davis that, unless he paid or made arrangement to pay the clerk’s fee for 

preparation of the clerk’s record and notify the Court of the actions taken within 21 

days from the date of the letter, the appeal would be dismissed for want of prosecution. 

TEX. R. APP. P. 37.3(b). More than 21 days have passed, and Davis has not made 
Davis v. Kirk Page 2

arrangement to pay the clerk’s fee for preparation of the clerk’s record and has not 

notified the Court of the actions taken.

Accordingly, this appeal is dismissed. Id.

Absent a specific exemption, the Clerk of the Court must collect filing fees at the 

time a document is presented for filing. TEX. R. APP. P. 12.1(b); Appendix to TEX. R. APP.

P., Order Regarding Fees (Amended Aug. 28, 2007, eff. Sept. 1, 2007). See also TEX. R.

APP. P. 5; 10TH TEX. APP. (WACO) LOC. R. 5; TEX. GOV’T CODE ANN. § 51.207(b); § 

51.941(a) (West 2005); and § 51.208 (West Supp. 2011). Under these circumstances, we 

suspend the rule and order the Clerk to write off all unpaid filing fees in this case. TEX.

R. APP. P. 2. The write-off of the fees from the accounts receivable of the Court in no 

way eliminates or reduces the fees owed.

TOM GRAY

Chief Justice

Before Chief Justice Gray,

Justice Davis, and

Justice Scoggins

Dismissed

Opinion delivered and filed March 28, 2012

[CV06]